Myelodysplastic syndromes: State of the art pathology, diagnosis and management

2013 ◽  
Vol 26 (4) ◽  
pp. 307-308 ◽  
Author(s):  
Pierre Fenaux
Author(s):  
Dale Bixby

This chapter guides the reader on the diagnosis and management of myeloproliferative neoplasms and myelodysplastic syndromes in hospitalized patients.


Author(s):  
Chris Bunch

The myelodysplastic syndromes (or myelodysplasias) comprise a spectrum of disorders characterized by dysplastic or ineffective haemopoiesis that leads to variable anaemia, neutropenia, and thrombocytopenia. There is often a degree of red-cell macrocytosis. The majority are clonal stem cell disorders in which the abnormal clone predominates and expands only slowly over a number of years. Myelodysplasias have a tendency to develop ultimately into acute leukaemia in some patients; for this reason, they are sometimes referred to as ‘preleukaemias’, even though two-thirds of patients will never develop this complication. This chapter addresses the causes, diagnosis, and management of myelodysplastic syndromes.


2018 ◽  
Vol 2 (Supplement_1) ◽  
pp. 60-62
Author(s):  
Renée Crisp ◽  
Sofía Grille ◽  
Carolina Belli ◽  
Lilián Diaz ◽  
Soledad Undurraga ◽  
...  

Drugs in R&D ◽  
2017 ◽  
Vol 17 (1) ◽  
pp. 91-96 ◽  
Author(s):  
Nuno Vicente ◽  
Luís Cardoso ◽  
Luísa Barros ◽  
Francisco Carrilho

2001 ◽  
Vol 16 (2) ◽  
pp. 73-86 ◽  
Author(s):  
C.M.G. Thomas ◽  
C.G.J. Sweep

Serum determinations of tumor markers are indispensable in the diagnosis and management of cancer, and therefore play an important role in clinical practice. After a short historical survey, we systematically review a number of contemporary aspects of serum tumor markers related to various organ systems, and briefly indicate possible future developments.


Sign in / Sign up

Export Citation Format

Share Document